Loading...

BDX

BDRX

BIODEXA PHARMACEUTICALS PLC

(BDRX)

2024 6-K

Preliminary Results Announc...

27 Mar '26

Filing Update

18 Mar '26

License Agreement

4 Feb '26

New CFO Appointment

6 Jan '26

6-K Filing

5 Jan '26

Public Offering Launched

18 Dec '25

Clinical Trial Approval

3 Nov '25

Financial Results Update

12 Sep '25

Trial Enrollment Update

18 Aug '25

Filing Update

31 Jul '25

Form 6-K Filing

15 Jul '25

AGM Results Confirmed

27 Jun '25

Shareholder Approval

13 Jun '25

Filing Summary

11 Jun '25

6-K Filing Summary

4 Jun '25

Filing Summary

30 May '25

Annual General Meeting

23 May '25

Filing Update

22 May '25

Filing Update

22 May '25

Warrant Price Reduction

15 May '25

Filing Update

12 May '25

General Meeting Results

2 May '25

Filing Notification

17 Apr '25

Preliminary Results

11 Apr '25

Filing Notification

10 Mar '25

Filing Confirmation

6 Mar '25

Filing Update

24 Feb '25

Filing Notification

13 Feb '25

Filing Summary

10 Feb '25

Company Filing Update

22 Jan '25

Capital Raise Agreement

17 Jan '25

Promissory Note Issued

27 Dec '24

Filing Confirmation

4 Dec '24

Nasdaq Compliance Regained

12 Nov '24

Filing Notification

7 Nov '24

Auditor Change

1 Nov '24

Delisting Appeal Success

15 Oct '24

Filing Report

4 Oct '24

Financial Update

26 Sep '24

Filing Update

19 Sep '24

Form 6-K Filing

16 Sep '24

Filing Submission

30 Aug '24

Fundraising Announcement

23 Jul '24

Filing Amendment

19 Jul '24

Fundraising Announcement

19 Jul '24

Filing Overview

16 Jul '24

Director Departure

5 Jul '24

Filing Overview

2 Jul '24

Company Filing Update

24 Jun '24

Filing Reported

13 Jun '24

Warrant Exercise Update

28 May '24

Warrant Inducement

22 May '24

Biodexa Filing Alert

21 May '24

Annual Report Filing

15 May '24

Filing Update

15 May '24

Filing Report

30 Apr '24

Licensing Agreement

26 Apr '24

Preliminary Results

19 Apr '24

Filing Notification

23 Feb '24

Company Update

22 Jan '24

External Links:

SEC

Biodexa Pharmaceuticals Plc announced that Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer, departed on July 4, 2024, with a consultant taking the interim role until a permanent successor is found.

AI Assistant

BIODEXA PHARMACEUTICALS PLC

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.